605177.SHG Zhejiang East Asia Pharmaceutical Co. Ltd.
- Market cap
- CNY 2.44B
- P/E
- -
- P/B
- 1.35x
- ROE
- -13.9%
- Dividend yield
- 0.35%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 605177.SHG undervalued?
Graham numberThe Graham number of Zhejiang East Asia Pharmaceutical Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang East Asia Pharmaceutical Co. Ltd. fundamental analysis
No fundamental analysis for Zhejiang East Asia Pharmaceutical Co. Ltd. yet.
Zhejiang East Asia Pharmaceutical Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang East Asia Pharmaceutical Co. Ltd.
Zhejiang East Asia Pharmaceutical Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules in China and internationally. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents, antineoplastic a…
Full company profileZhejiang East Asia Pharmaceutical Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang East Asia Pharmaceutical Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 684M | 729M | 857M | 988M | 882M | 712M | 1.18B | 1.36B | 1.20B | 940M | 932M |
| Gross Profit | 213M | 219M | 275M | 335M | 294M | 191M | 266M | 349M | 194M | 222M | 223M |
| Operating Income | 79.4M | 68.0M | 133M | 197M | 134M | 78.9M | 121M | 137M | -102M | -30.5M | -79.7M |
| EBITDA | 151M | 142M | 193M | 258M | 194M | 146M | 208M | 247M | 16.2M | 84.1M | -216M |
| Net Income | 66.7M | 55.7M | 109M | 168M | 114M | 68.5M | 104M | 121M | -101M | -82.4M | -237M |
| EPS | 0.89 | 0.71 | 1.28 | 1.98 | 1.31 | 0.60 | 0.92 | 0.97 | -0.90 | -0.72 | -2.06 |
| Balance Sheet | |||||||||||
| Total Assets | 1.03B | 1.17B | 1.09B | 1.11B | 2.08B | 2.25B | 2.47B | 3.34B | 3.56B | 3.34B | 3.07B |
| Total Liabilities | 600M | 534M | 383M | 259M | 352M | 493M | 632M | 1.33B | 1.68B | 1.53B | 1.36B |
| Shareholders' Equity | 426M | 632M | 711M | 848M | 1.73B | 1.76B | 1.84B | 2.02B | 1.87B | 1.81B | 1.70B |
| Cash & Short-term Investments | 73.2M | 189M | 112M | 133M | 989M | 606M | 532M | 711M | 563M | 244M | 255M |
| Total Debt | 330M | 279M | 98.5M | 20.0M | 10.0M | 2.38M | 123M | 707M | 781M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 54.4M | 91.7M | 144M | 217M | 147M | -23.6M | -70.4M | -84.1M | -157M | -269M | - |
| Capital Expenditure | 40.1M | 28.2M | 29.5M | 57.8M | 61.1M | 122M | 87.8M | 227M | 212M | 74.3M | 32.5M |
| Free Cash Flow | 14.2M | 63.5M | 114M | 159M | 85.8M | -146M | -158M | -312M | -368M | -343M | 71.1M |
| Ratios | |||||||||||
| ROE | 15.7% | 8.8% | 15.4% | 19.8% | 6.6% | 3.9% | 5.7% | 6.0% | -5.4% | -4.6% | -13.9% |
| ROA | 6.5% | 4.8% | 10.0% | 15.2% | 5.5% | 3.0% | 4.2% | 3.6% | -2.8% | -2.5% | -7.7% |
| Net Profit Margin | 9.8% | 7.6% | 12.8% | 17.0% | 13.0% | 9.6% | 8.9% | 8.9% | -8.4% | -8.8% | -25.4% |
| Debt to Equity | 0.77x | 0.44x | 0.14x | 0.02x | 0.01x | 0.00x | 0.07x | 0.35x | 0.42x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang East Asia Pharmaceutical Co. Ltd. dividends
- Dividend yield
- 0.35%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 4, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 8.61M | 0.08 | - |
| 2024 | CNY 41.6M | 0.37 | - |
| 2023 | CNY 36.3M | 0.29 | 29.9% |
| 2022 | CNY 22.7M | 0.20 | 21.8% |
| 2021 | CNY 39.8M | 0.35 | 58.1% |
| 2020 | CNY 15.3M | 0.18 | 13.4% |
| 2019 | CNY 64.9M | 0.76 | 38.5% |
| 2018 | 8.01M | 0.09 | 7.3% |
| 2017 | 17.1M | 0.22 | 30.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Zhejiang East Asia Pharmaceutical Co. Ltd.
- Insiders 56.26%
- Institutions 0.71%
- Public & others 43.03%
- Shares outstanding 115M
- Free float 54.5M
Zhejiang East Asia Pharmaceutical Co. Ltd. company profile
- Company name
- Zhejiang East Asia Pharmaceutical Co. Ltd.
- Ticker
- 605177.SHG
- ISIN
- CNE1000077G5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,514
- Fiscal year end
- December
- Address
- Chamber of Commerce Building, Taizhou, China, 318020
- Phone
- 86 57 6891 85675
- Website
- eapharm.cn
About Zhejiang East Asia Pharmaceutical Co. Ltd.
Zhejiang East Asia Pharmaceutical Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules in China and internationally. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents, antineoplastic agents and tumor adjuvant drugs, and other products. The company's products are used in cardiovascular, anti-aging, dementia, digestive system, diabetic neuropathy, anti-pathogenic microorganisms, infection, and central nervous system fields. It exports its products. The company was founded in 1998 and is headquartered in Taizhou, China.
Zhejiang East Asia Pharmaceutical Co. Ltd. management
6- Mr. Cheng ChiGM & Chairman · born 1984
- Ms. Xiaomin WangFinancial Manager · born 1971
- Mr. Daomin XiaDeputy GM & Director · born 1963
- Mr. Jianbo ZhouSecretary to the Board · born 1986
- Ms. Lingzhi ChenDeputy General Manager · born 1976
- Xue Hua DaiAccounting Supervisor